VANISHing the progression of cardiac abnormalities in hypertrophic cardiomyopathy with early use of valsartan?

Affiliations

¹ Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant' Andrea Hospital, Via di Grottarossa, 1035-1039, Rome 00189, Italy.
² Department of Cardiovascular and Pulmonary Sciences, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Catholic University School of Medicine, Largo A. Gemelli 8, Rome 00168, Italy.

Comment

Massimo Volpe et al. Eur Heart J. 2022.

. 2022 Jan 25;43(3):181-182.

doi: 10.1093/eurheartj/ehab787.

¹ Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant' Andrea Hospital, Via di Grottarossa, 1035-1039, Rome 00189, Italy.
² Department of Cardiovascular and Pulmonary Sciences, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Catholic University School of Medicine, Largo A. Gemelli 8, Rome 00168, Italy.

No abstract available

Comment on

Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.
Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Vargas JD, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL; VANISH Investigators; Burns KM, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E. Ho CY, et al. Nat Med. 2021 Oct;27(10):1818-1824. doi: 10.1038/s41591-021-01505-4. Epub 2021 Sep 23. Nat Med. 2021. PMID: 34556856 Free PMC article. Clinical Trial.